PlusVitech Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3.49M
- Investors
-
7
PlusVitech General Information
Description
Developer of pharmaceutical treatments designed for non-invasive genetic cancer detection. The company's therapies focus on small-molecule, monoclonal antibodies instead of painful and time-consuming tissue biopsies, enabling doctors to detect and treat cancers early.
Contact Information
Website
www.plusvitech.comCorporate Office
- Calle Herreros, 33
- Mairena del Alcor
- 41510 Sevilla
- Spain
Corporate Office
- Calle Herreros, 33
- Mairena del Alcor
- 41510 Sevilla
- Spain
PlusVitech Timeline
PlusVitech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 18-Dec-2025 | $3.49M | Completed | Clinical Trials - Phase 1 | ||
| 5. Grant | 16-May-2024 | Completed | Clinical Trials - Phase 1 | |||
| 4. Accelerator/Incubator | 26-Jul-2023 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | 17-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Angel (individual) | 18-Nov-2019 | $218K | $423K | Completed | Startup | |
| 1. Angel (individual) | 16-Jan-2017 | $205K | $205K | Completed | Startup |
PlusVitech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | 5,960 | $1.179946 | $38.59 | $38.59 | 1x | $38.59 | 13.13% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
PlusVitech Patents
PlusVitech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026214846-A1 | Nano-formulation process | Pending | 08-Apr-2025 | ||
| WO-2026215278-A1 | Nano-formulation process | Pending | 08-Apr-2025 | ||
| WO-2022253748-A1 | Combinations for the treatment of hpv | Inactive | 03-Jun-2021 | ||
| WO-2022243430-A1 | Treatment of acne | Inactive | 20-May-2021 | ||
| WO-2022234110-A1 | Gamma-aminobutyric acid derivatives for use in cancer therapy | Inactive | 07-May-2021 | A61K31/197 |
PlusVitech Signals
PlusVitech Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| INNVIERTE SICC | Government | |||
| MassChallenge | Accelerator/Incubator | |||
| Capital Global Partners | Venture Capital | Minority | ||
| Homu Health Ventures | Venture Capital | Minority | ||
| 3Fs (Spain) | Angel Group | Minority |
PlusVitech FAQs
-
When was PlusVitech founded?
PlusVitech was founded in 2013.
-
Where is PlusVitech headquartered?
PlusVitech is headquartered in Sevilla, Spain.
-
What is the size of PlusVitech?
PlusVitech has 2 total employees.
-
What industry is PlusVitech in?
PlusVitech’s primary industry is Biotechnology.
-
Is PlusVitech a private or public company?
PlusVitech is a Private company.
-
What is PlusVitech’s current revenue?
The current revenue for PlusVitech is .
-
How much funding has PlusVitech raised over time?
PlusVitech has raised $4.5M.
-
Who are PlusVitech’s investors?
INNVIERTE SICC, MassChallenge, Capital Global Partners, Homu Health Ventures, and 3Fs (Spain) are 5 of 7 investors who have invested in PlusVitech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process